Eravacycline for the treatment of intra-abdominal infections

Bibliography

• Boucher HW, Talbot GH, Bradley JS, et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 2009;48:1-12
   PubMed Web of Science ®Google Scholar
• Hersh AL, Newland JG, Beekmann SE, et al. Unmet medical need in infectious diseases. Clin Infect Dis 2012;54:1677-8
   PubMed Web of Science ®Google Scholar
• Sanchez-Pescador R, Brown JT, Roberts M, Urdea MS. Homology of the TetM with translational elongation factors: implications for potential modes of tetM-conferred tetracycline resistance. Nucleic Acids Res 1988;16:1218
   PubMed Web of Science ®Google Scholar
• Kanj SS, Kanafani ZA. Current concepts in antimicrobial therapy against resistant gram-negative organisms: extended-spectrum beta-lactamase-producing Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae, and multidrug-resistant Pseudomonas aeruginosa. Mayo Clin Proc 2011;86:250-9
   PubMed Web of Science ®Google Scholar
• Gupta N, Limbago BM, Patel JB, Kallen AJ. Carbapenem-resistant Enterobacteriaceae: epidemiology and prevention. Clin Infect Dis 2011;53:60-7
   PubMed Web of Science ®Google Scholar
• Munoz-Price LS, Poirel L, Bonomo RA, et al. Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases. Lancet Infect Dis 2013;13:785-96
   PubMed Web of Science ®Google Scholar
• Correa L, Martino MD, Siqueira I, et al. A hospital-based matched case-control study to identify clinical outcome and risk factors associated with carbapenem-resistant Klebsiella pneumoniae infection. BMC Infect Dis 2013;13:80
   PubMed Web of Science ®Google Scholar
• Nordmann P, Cuzon G, Naas T. The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria. Lancet Infect Dis 2009;9:228-36
   PubMed Web of Science ®Google Scholar
• Peleg AY, Hooper DC. Hospital-acquired infections due to gram-negative bacteria. N Engl J Med 2010;362:1804-13
   PubMed Web of Science ®Google Scholar
• Qureshi ZA, Paterson DL, Peleg AY, et al. Clinical characteristics of bacteraemia caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae in the era of CTX-M-type and KPC-type beta-lactamases. Clin Microbiol Infect 2012;18:887-93
   PubMed Web of Science ®Google Scholar
• Sunenshine RH, Wright MO, Maragakis LL, et al. Multidrug-resistant Acinetobacter infection mortality rate and length of hospitalization. Emerg Infect Dis 2007;13:97-103
   PubMed Web of Science ®Google Scholar
• Nelson ML, Levy SB. The history of the tetracyclines. Ann N Y Acad Sci 2011;1241:17-32
   PubMed Web of Science ®Google Scholar
• Charest MG, Lerner CD, Brubaker JD, et al. A convergent enantioselective route to structurally diverse 6-deoxytetracycline antibiotics. Science 2005;308:395-8
   PubMed Web of Science ®Google Scholar
• Wright PM, Seiple IB, Myers AG. The evolving role of chemical synthesis in antibacterial drug discovery. Angew Chem Int Ed Engl 2014;53:8840-69
   PubMed Web of Science ®Google Scholar
• Xiao XY, Hunt DK, Zhou J, et al. Fluorocyclines. 1. 7-fluoro-9-pyrrolidinoacetamido-6-demethyl-6-deoxytetracycline: a potent, broad spectrum antibacterial agent. J Med Chem 2012;55:597-605
   PubMed Web of Science ®Google Scholar
• Hunt D, Xiao X, Clark R, et al. TP-434 is a novel broad-spectrum fluorocycline. Presented at 50th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; 12 – 15 September 2010; Boston, MA, USA
   Google Scholar
• Chopra I. Glycylcyclines: third-generation tetracycline antibiotics. Curr Opin Pharmacol 2001;1:464-9
   PubMedGoogle Scholar
• Roberts MC. Update on acquired tetracycline resistance genes. FEMS Microbiol Lett 2005;245:195-203
   PubMed Web of Science ®Google Scholar
• Burdett V. Tet(M)-promoted release of tetracycline from ribosomes is GTP dependent. J Bacteriol 1996;178:3246-51
   PubMed Web of Science ®Google Scholar
• Connell SR, Tracz DM, Nierhaus KH, Taylor DE. Ribosomal protection proteins and their mechanism of tetracycline resistance. Antimicrob Agents Chemother 2003;47:3675-81
   PubMed Web of Science ®Google Scholar
• Connell SR, Trieber CA, Dinos GP, et al. Mechanism of Tet(O)-mediated tetracycline resistance. EMBO J 2003;22:945-53
   PubMed Web of Science ®Google Scholar
• Sanchez GV, Master RN, Clark RB, et al. Klebsiella pneumoniae antimicrobial drug resistance, United States, 1998-2010. Emerg Infect Dis 2013;19:133-6
   PubMed Web of Science ®Google Scholar
• Thaker M, Spanogiannopoulos P, Wright GD. The tetracycline resistome. Cell Mol Life Sci 2010;67:419-31
   PubMed Web of Science ®Google Scholar
• Bryan A, Shapir N, Sadowsky MJ. Frequency and distribution of tetracycline resistance genes in genetically diverse, nonselected, and nonclinical Escherichia coli strains isolated from diverse human and animal sources. Appl Environ Microbiol 2004;70:2503-7
   PubMed Web of Science ®Google Scholar
• Peterson LR. A review of tigecycline, the first glycylcycline. Int J Antimicrob Agents 2008;32(Suppl 4):S215-22
   PubMedGoogle Scholar
• Grossman TH, Starosta AL, Fyfe C, et al. Target- and resistance-based mechanistic studies with TP-434, a novel fluorocycline antibiotic. Antimicrob Agents Chemother 2012;56:2559-64
   PubMed Web of Science ®Google Scholar
• Tuckman M, Petersen PJ, Projan SJ. Mutations in the interdomain loop region of the tetA(A) tetracycline resistance gene increase efflux of minocycline and glycylcyclines. Microb Drug Resist 2000;6:277-82
   PubMed Web of Science ®Google Scholar
• Fyfe C, Sutcliffe J, Grossman TH. Susceptibility of tetracyclines to Tet(A) resistance is independent of interdomain loop sequence. Antimicrob Agents Chemother 2013;57:2430-1
   PubMed Web of Science ®Google Scholar
• Draper MP, Weir S, Macone A, et al. Mechanism of action of the novel aminomethylcycline antibiotic omadacycline. Antimicrob Agents Chemother 2014;58:1279-83
   PubMed Web of Science ®Google Scholar
• Macone AB, Caruso BK, Leahy RG, et al. In vitro and in vivo antibacterial activities of omadacycline, a novel aminomethylcycline. Antimicrob Agents Chemother 2014;58:1127-35
   PubMed Web of Science ®Google Scholar
• Clark RB, Hunt DK, He M, et al. Fluorocyclines. 2. Optimization of the C-9 side-chain for antibacterial activity and oral efficacy. J Med Chem 2012;55:606-22
   PubMed Web of Science ®Google Scholar
• Sutcliffe JA, O’Brien W, Fyfe C, Grossman TH. Antibacterial activity of eravacycline (TP-434), a novel fluorocycline, against hospital and community pathogens. Antimicrob Agents Chemother 2013;57:5548-58
   PubMed Web of Science ®Google Scholar
• Grossman TH, O’Brien WO, Fyfe C, Sutcliffe JA. Eravacycline is potent against third generation cephalosporin- and carbapenem-resistant Enterobacteriaceae, carbapenem-resistant Acinetobacter baumannii, and has isolate-specific bactericidal activity [abstract C-1374]. 54th Annual ICAAC; 5 – 9 September 2014
   Google Scholar
• McAleese F, Petersen P, Ruzin A, et al. A novel MATE family efflux pump contributes to the reduced susceptibility of laboratory-derived Staphylococcus aureus mutants to tigecycline. Antimicrob Agents Chemother 2005;49:1865-71
   PubMed Web of Science ®Google Scholar
• European Committee on Antimicrobial Susceptibility Testing, Breakpoint tables for interpretation of MICs and zone diameters, Version 3.1, 2013. Available from: http://www.eucast.org/clinical_breakpoints [Accessed 10 July 2014]
   Google Scholar
• Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, approved standard. 11th edition. Document M7-A8 Clinical and Laboratory Standards Institute; Wayne, PA, USA: 2012
   Google Scholar
• O’Brien W, Sutcliffe J, Grossman T. TP-434 is Synergistic in vitro with amphotericin B, fluconazole and caspofungin against Candida spp. Presented at 51th Annual Interscience Conference on Antimcrobial Agents and Chemotherapy; 17 – 20 September 2011; Chicago, IL, USA
   Google Scholar
• Ronn M, Dunwoody N, Sutcliffe J. Pharmacokinetics of TP-434 in mouse, rat, dog, monkey and chimpanzee. Presented at 50th Annual Interscience Conference on Antimcrobial Agents and Chemotherapy; 12 – 15 September 2010; Boston, MA, USA
   Google Scholar
• Sutcliffe J. Antibiotics in development targeting protein synthesis. Ann N Y Acad Sci 2011;1241:122-52
   PubMed Web of Science ®Google Scholar
• Singh RSP, Falcao NMS, Sutcliffe J, Derendorf H. Plasma protein binding of eravacycline in mouse, rat, rabbit, cynomolgus monkey, African green monkey and human using microdialysis [abstract A-015]. 53rd Annual ICAAC; 10 – 13 September 2013
   Google Scholar
• Petersen PJ, Jacobus NV, Weiss WJ, et al. In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936). Antimicrob Agents Chemother 1999;43:738-44
   PubMed Web of Science ®Google Scholar
• Yue CS, Sutcliffe JA, Colucci P, et al. Population pharmacokinetic modeling of TP-434, a novel fluorocycline, following single and multiple dose administration. Presented at 50th Annual Interscience Conference on Antimcrobial Agents and Chemotherapy; 12 – 15 September 2010; Boston, MA, USA
   Google Scholar
• Horn P, Sutcliffe J, Walpole S, Leighton A. Pharmacokinetics, safety, and tolerability of a novel fluorocycline, TP-434, following multiple dose administration. Presented at 49th Meeting of the Infectious Disease Society of America; 20 – 23 October 2011; Boston, MA, USA
   Google Scholar
• Leighton A, Zupanets I, Bezugla N, et al. Broad-spectrum fluorocycline TP-434 has oral bioavailability in humans. Presented at 21st European Congress of Clinical Microbiology and Infectious Diseases; 7 – 10 May 2011; Milan, Italy
   Google Scholar
• Christ D, Sutcliffe J. TP-434 is metabolically stable and has low potential for drug-drug interactions [abstract F1-2162]. 50th annual ICAAC; 12 – 15 September 2010; Boston, MA
   Google Scholar
• Cunha BA. Pharmacokinetic considerations regarding tigecycline for multidrug-resistant (MDR) Klebsiella pneumoniae or MDR Acinetobacter baumannii urosepsis. J Clin Microbiol 2009;47:1613
   PubMed Web of Science ®Google Scholar
• Sutcliffe J, Grossman T, Ronn M, et al. TP-434 has potential to treat complicated urinary tract infections (cUTI). Presented at 51th Annual Interscience Conference on Antimcrobial Agents and Chemotherapy; 17 – 20 September 2011; Chicago, IL, USA
   Google Scholar
• O’Brien W, Sutcliffe J, Grossman T. Eravacycline (TP-434) is active in vitro against biofilms formed by uropathogenic Escherichia coli. Presented at 52th Annual Interscience Conference on Antimcrobial Agents and Chemotherapy; 9 – 12 September 2012; San Francisco, CA, USA
   Google Scholar
• Labthavikul P, Petersen PJ, Bradford PA. In vitro activity of tigecycline against Staphylococcus epidermidis growing in an adherent-cell biofilm model. Antimicrob Agents Chemother 2003;47:3967-9
   PubMed Web of Science ®Google Scholar
• Raad I, Hanna H, Jiang Y, et al. Comparative activities of daptomycin, linezolid, and tigecycline against catheter-related methicillin-resistant Staphylococcus bacteremic isolates embedded in biofilm. Antimicrob Agents Chemother 2007;51:1656-60
   PubMed Web of Science ®Google Scholar
• McConeghy KW, LaPlante KL. In vitro activity of tigecycline in combination with gentamicin against biofilm-forming Staphylococcus aureus. Diagn Microbiol Infect Dis 2010;68:1-6
   PubMed Web of Science ®Google Scholar
• Szezuka E, Kaznowsky A. Antimicrobial activity of tigecycline alone or in combination with rifampin against staphylococcus epidermidis in biofilm. Folia Microbiol (Praha) 2014;59:283-8
   PubMed Web of Science ®Google Scholar
• Connors KP, Housman ST, Pope JS, et al. Phase I, open-label, safety and pharmacokinetic study to assess bronchopulmonary disposition of intravenous eravacycline in healthy men and women. Antimicrob Agents Chemother 2014;58:2113-18
   PubMed Web of Science ®Google Scholar
• Fyfe C, Grossman T, O’Brien W, et al. The novel broad spectrum fluorocycline TP434 is active against MDR gram negative pathogens. Presented at 21st European Congress of Clinical Microbiology and Infectious Diseases; 7 – 10 May 2011; Milan, Italy
   Google Scholar
• Murphy T, Slee A, Sutcliffe J. TP-434 is highly efficacious in animal models of infection. Presented at 50th Annual Interscience Conference on Antimcrobial Agents and Chemotherapy; 12 – 15 September 2010; Boston, MA, USA
   Google Scholar
• Solomkin JS, Mazuski JE, Bradley JS, et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Clin Infect Dis 2010;50:133-64
   PubMed Web of Science ®Google Scholar
• Solomkin JS, Ramesh MK, Cesnauskas G, et al. Phase 2, randomized, double-blind study of the efficacy and safety of two dose regimens of eravacycline versus ertapenem for adult community-acquired complicated intra-abdominal infections. Antimicrob Agents Chemother 2014;58:1847-54
   PubMed Web of Science ®Google Scholar
• Namias N, Solomkin JS, Jensen EH, et al. Randomized, multicenter, double-blind study of efficacy, safety, and tolerability of intravenous ertapenem versus piperacillin/tazobactam in treatment of complicated intra-abdominal infections in hospitalized adults. Surg Infect (Larchmt) 2007;8:15-28
   PubMedGoogle Scholar
• Sutcliffe J, Ronn M, Leighton A, et al. Phase 1 single ascending dose study of a broad-spectrum fluorocycline, TP-434. Presented at 50th Annual Interscience Conference on Antimcrobial Agents and Chemotherapy; 12 – 15 September 2010; Boston, MA, USA
   Google Scholar
• Sutcliffe J, Ronn M, Leighton A, Sprenger C. Phase 1 single and multiple ascending dose studies of a broad-spectrum fluorocycline, TP-434 [abstract A1-027]. 50th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; 12 – 15 September 2010
   Google Scholar
• Babinchak T, Ellis-Grosse E, Dartois N, et al. The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data. Clin Infect Dis 2005;41(Suppl 5):S354-67
   PubMed Web of Science ®Google Scholar
• Horn PT, Redican S, Wei X, et al. Eravacycline does not prolong corrected QT intervals in a thorough QT study conducted in healthy subjects. Presented at 24th European Congress of Clinical Microbiology and Infectious Diseases; 10 – 13 May 2014; Barcelona, Spain
   Google Scholar
• Carbapenemase-producing bacteria in Europe. Interim results from the European survey on carbapenemase-producing Enterobacteriaceae (EuSCAPE) project. 2013. Available from: www.ecdc.europa.eu
   Google Scholar